Genomics

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #Toxicology

Data-mining Open Source Databases for Drug Repositioning Using Graph-Based Technique

Data-mining Open Source Databases for Drug Repositioning Using Graph-Based Technique By Dr Ken McGarry & Ukeme Daniel The analysis of ‘Big Data’ has great potential in drug discovery; however complications arise in integrating this data in a principled and coherent way. An important statistical tool to manage complexity is that… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Advancing the Promise of Therapeutic Genomic Editing

There is no excerpt because this is a protected post. To read this content in full, you need to login. Not yet a DDW member? Join now for FREE – it takes less than 2 minutes! Username or E-mail Password Remember Me    … Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Reconfiguring Drug Discovery Through Innovative Partnerships

Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biobanking #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #Molecular medicine #Oncology #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Best Practices In Biobanking

Best Practices In Biobanking By Kiara W. Biagioni Biobanks or biorepositories are facilities that collect, process, store and distribute biospecimens and associated data, mainly for biological and medical research. They constitute a crucial resource, supporting cutting-edge investigation in fields such as oncology, genomics and personalised medicine, and the development of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Oncology Target Discovery by RNAi: The past, present, and future perspectives

Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microbiome #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

New Tools Bring Greater Understanding to Cellular Metabolism Research

New Tools Bring Greater Understanding to Cellular Metabolism Research By Dr John Comley The links between mitochondrial dysfunction and various diseases and pathological conditions are being increasingly revealed, such that mitochondrial analyses have gained renewed interest from both the academic research and drug discovery labs. This revival of interest in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genetics #Genomics #High Content Screening #High throughput screening #Imaging #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

The CRISPR/Cas9 System: Cutting a path for rapid generation of more translational animal models.

The CRISPR/Cas9 System: Cutting a path for rapid generation of more translational animal models. By Dr Kevin M. Gamber The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the modification of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #Lead discovery #Metabolomics #Microbiology #Molecular medicine #Oncology #Pathology #PCR #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Translational #Translational chemistry

Automating The Drive Towards Personalised Medicine

Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Target validation #Therapeutics

Library Logistics: Managing Comprehensive Compound Collections

Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. As highthroughput technologies have become the norm, Bayer HealthCare, a global… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Metabolomics #Molecular medicine #Oncology #PCR #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Predictive safety & research methods: The keys to precision medicine?

Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Building New Models of Drug Discovery in Europe – The Innovative Medicines Initiative

Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #PCR #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Digital PCR (dPCR) and Real-Time PCR (qPCR): A time and place for each

Digital PCR (dPCR) and Real-Time PCR (qPCR): A time and place for each By Dr George Karlin-Neumann and Dr Rachel Scott When it comes to DNA research, scientists often find themselves weighing digital PCR (dPCR) against the more established quantitative real-time PCR (qPCR). Which technique is better to use? The… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays By Dr Nikolai Schwabe and Katherine Catchpole The progression from health to disease is marked by significant biological changes within an individual (1). Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Precision medicine #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Gene Editing: Re-writing Genomes With Targetable Nucleases

Gene Editing: Re-writing Genomes With Targetable Nucleases By Dr Dana Carroll We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analytical chemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Preclinical #Sequencing #Stem cells

The Great Neuro-Pipeline Brain Drain – Why Big Pharma Hasn’t Given Up On CNS Disorders

The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't Given Up On CNS Disorders By Julia Skripka-Serry Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Read More

#Archive